Drugs / CD8+T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07414979 | Aug 2026 → Mar 2028 expected | leptomeningeal melanoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD8+T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07414979 ↗ |
| Modality | Cell therapy | “intrathecal infusion of TAA-specific T cells” NCT07414979 ↗ |
| Route | Other | “Given by infusion” NCT07414979 ↗ |